SIMULTANEOUS DETERMINATION OF FIVE MAJOR CONSTITUENTS IN THE EFFECTIVE FRACTIONS OF HUANGQICHIFENG MEDICINAL BROTH, BY UPLC-MS/MS

被引:4
作者
Gu, Yulong [1 ,2 ]
Liu, Bin [1 ]
Jiang, Yanyan [1 ]
Xu, Yu [2 ]
机构
[1] Beijing Univ Chinese Med, Sch Chinese Mat Medica, Beijing 100102, Peoples R China
[2] Minzu Univ China, Inst China Minor Tradit Med, Beijing, Peoples R China
关键词
calycosin; UPLC-MS/MS; paeoniflorin; prim-O-glucosylcimifugin; ononin; formononetin; PAEONIFLORIN; RATS;
D O I
10.1080/10826076.2013.794735
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
An UPLC method coupled with tandem quadrupole mass spectrometry (MS/MS) was established for the simultaneous quantitative analysis of five major constituents in the effective fractions of Huangqichifeng Medicinal Broth (EFHQCF), namely paeoniflorin (PA), prim-O-glucosylcimifugin (PR), ononin (ON), calycosin (CA), and formononetin (FO). The analytes were analyzed on an ACQUITY BEH C-18 VanGuard precolumn and an ACQUITY UPLC BEH C-18 column using gradient elution. The mobile phase A was ammonium acetate (10mM) in water containing 0.2% acetic acid (v/v); mobile phase B was ammonium acetate (10mM) in methanol containing 0.2% acetic acid (v/v). The solvent flow rate was 0.25mL/min. The retention times of PA, PR, ON, CA, and FO were 9.9min, 18.2min, 26.6min, 30.6min, and 35.7min, respectively. The investigated compounds were detected by MS/MS using a negative ion multiple reaction monitoring mode for the simultaneous quantitative detection. The limits of detection ranged from 0.001ug/mL to 0.043 mu g/mL, and the limits of quantitation varied from 0.003 mu g/mL to 0.148 mu g/mL. Moreover, the linearities (r (2)>0.999) and recoveries (from 96.34% to 104.75%) were acceptable. Therefore, the present study suggested that this UPLC-MS/MS method should be reliable and could be used to control the quality of EFHQCF.
引用
收藏
页码:1404 / 1415
页数:12
相关论文
共 35 条
[1]  
[曹悦 CAO Yue], 2009, [时珍国医国药, Lishizhen Medicine and Materia Medica Research], V20, P1079
[2]  
Chen Yin, 2007, Yaoxue Xuebao, V42, P1147
[3]  
Du X. G., 2008, J CHINESE PHARM SCI, V17, P230
[4]  
Han Gui-qiu, 2011, Zhongguo Yaolixue Tongbao, V27, P671, DOI 10.3969/j.issn.1001-1978.2011.05.018
[5]  
[Hou Yuanyuan 侯媛媛], 2010, [南开大学学报. 自然科学版, Acta Scientiarum Naturalium Universitatis Nankaiensis], V43, P29
[6]  
[胡柳 Hu Liu], 2004, [中国药学杂志, Chinese Pharmaceutical Journal], V39, P895
[7]   Systemic Risk Contributions [J].
Huang, Xin ;
Zhou, Hao ;
Zhu, Haibin .
JOURNAL OF FINANCIAL SERVICES RESEARCH, 2012, 42 (1-2) :55-83
[8]  
Ji L. X., 2010, DRUG EVAL RES, V33, P233
[9]  
Jiang YY., 2006, J BUCM, V29, P128
[10]  
Jianhua X., 2002, CHIN REM CLIN, V2, P157